Cansu Cimen Bozkus

List of Publications by Year
in descending order

16 papers	1,711 citations	1307594 7 h-index	1199594 12 g-index
16 all docs	16 docs citations	16 times ranked	5543 citing authors

#	Article	IF	Citations
1	Abstract 1379: Discovery of tumor-associated, immunogenic peptides presented in a patient-derived, mutant calreticulin-driven myeloproliferative neoplasm cell line. Cancer Research, 2022, 82, 1379-1379.	0.9	0
2	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
3	PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Advances, 2021, 5, 5086-5097.	5.2	16
4	Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. Cancer Cell, 2021, 39, 1187-1189.	16.8	3
5	Lynch Syndrome and MSI-H Cancers: From Mechanisms to â€œOff-The-Shelfâ€•Cancer Vaccines. Frontiers in Immunology, 2021, 12, 757804.	4.8	31
6	A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. STAR Protocols, 2021, 2, 100758.	1.2	12
7	772â€…MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2021, 9, A807-A807.		0
8	334â€…Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients. , 2021, 9, A360-A360.		0
9	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 2020, 183, 1634-1649.e17.	28.9	103
10	Long-lasting SARS-CoV-2-specific T cell memories. Nature Reviews Immunology, 2020, 20, 593-593.	22.7	1
11	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	14.3	1,387
12	SARS-CoV-2-specific T cells without antibodies. Nature Reviews Immunology, 2020, 20, 463-463.	22.7	3
13	Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms. Blood, 2020, 136, 14-15.	1.4	6
14	444â€…MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2020, , .		0
15	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery, 2019, 9, 1192-1207.	9.4	65
16	Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cellâ€“Mediated Control of T Cell Immunity. Journal of Immunology, 2015, 195, 5237-5250.	0.8	74